Table 3 Cox survival analysis in the > 6 months group

Gender(male)

5.540(0.712–43.083)

Age, y (≥ 65)

1.464(0.492–4.357)

Tumor location

 Bilateral

Reference

 Right

1.256(0.154–10.279)

 Left

0.765(0.075–0.973)

Cancer type

 SCLC

Reference

 Adenocarcinoma

N/A

 Squamous-cell carcinoma

N/A

Stage

 I

Reference

 II

N/A

 III

15.192(1.675–137.826)

 IV

12.715(1.556–103.866)

 Unknown

2.047(0.128–32.788)

Smoking

3.525(0.768–16.179)

System involved

 Pulmonary only

Reference

 Extrapulmonary only

N/A

 Pulmonary and extrapulmonary

N/A

Tuberculosis retreatment

 No

Reference

 Yes

0.502(0.065–3.872)

Anti-PD-(L)1 therapy

 No

Reference

 Yes

1.430(0.186–11.010)

 Surgery

0.079(0.021–0.296)

0.193(0.038–0.970)

ECOG Performance Status

12.866(2.730–60.638)

 0–2

Reference

 3–5

39.118(9.852–155.313)

Chemotherapy

 No

Reference

 Yes

0.783(0.241–2.546)

Targeted therapy

 No

Reference

 Yes

0.872(0.192–3.968)

Radiotherapy

 No

Reference

 Yes

0.450(0.058–3.470)

CRP(mg/L),n (%)

  < 10

Reference

 10–50

6.762(0.598–76.462)

  > 50

11.485(1.165–113.215)

IL-1β

 Normal

Reference

 Higher than normal

0.488(0.059–4.060)

IL-2R

 Normal

Reference

 Higher than normal

4.202(0.503–35.074)

IL-6

 Normal

Reference

Reference

 Higher than normal

35.307(N/A)

N/A

TNF-α

 Normal

Reference

 Higher than normal

1.230(0.135–11.173)

IGRA

 Negative

Reference

 Positive

1.286(0.159–10.383)

Cavity

 No

Reference

 Yes

1.927(0.629–5.903)